Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories


AltPep unpacks $23.1m round
University of Washington spinout AltPep will use the money to advance work on its lead asset that targets Alzheimer’s disease.
J-Pharma jacks series D up to $21m
Fidelity provided a $4.8m second tranche after a first close featuring vehicles for Kyushu University and Osaka University.
SpyGlass observes $27.5m
The eye disease device developer has raised series B funding to advance research originating from University of Colorado's s Sue Anschutz-Rodgers Eye Center.
Neuros Medical implants $38.5m
CWRU‘s pain neurostimulation spinout has secured series BB funding ahead of a 180-patient trial.
First Light switches on $25m
OSI has reinvested in the Oxford fusion energy spinout now set to expand its R&D capacity and headcount.
Exo Therapeutics executes $25m series A
The exosite drug developer has launched publicly to advance research from Harvard University and Salk Institute for Biological Studies. decodes $32m
Stanford-StartX Fund has backed in a series B round that boosted the software developer sourcing platform’s overall funding to at least $46m.
InnoSkel sets out with $24.3m
Spun out of University of Côte d’Azur and Inserm, InnoSkel expects to fund clinical work to address a form of skeletal dysplasia that causes dwarfism.

Other News

Deepcell caps $20m series A
Stanford University supplied capital to help its AI cell analysis spinout Deepcell close its second funding round.
Brainbox deduces $23m series A
The Virginia Tech-allied brain injury diagnosis software company attracted Virginia Tech Carilion Innovation Fund in what appears to be its first round of funding.
Anybotics slides $22.5m under its hood
ETH Zurich industrial robotics spinout Anybotics has collected series A capital from investors led by Swisscom Ventures.
Alphabet finds Spotlight in $30m series A
The gene-editing drug developer has completed its first publicly announced round to advance UC and ETH Zürich research.
Proscia determines $23m
Johns Hopkins and Pitt-linked digital pathology platform Proscia has increased its funding total to $35m with a series B round involving Hitachi Ventures.
Investors endow Endomag with $20m
Existing backers including Draper Esprit and Sussex Place Ventures have reinvested to bring Endomag’s overall funding to above $43m.

Editor's Picks

Tel Aviv partners with Tata
Tel Aviv University announces $20m commercialisation fund with Tata Industries.
UK graphene research nets $35m backing
Cell Medica raises $26.5m
Invesco Perpetual, the fund manager, and Imperial Innovations, the London Stock Exchange-listed spin-off from Imperial College London, are joined by The Cancer Prevention and Research Institute of Texas and the Wellcome Trust supporting Cell Medica's growth.
Revolymer sticks to AIM in IPO
Revolymer, which makes chewing gum that is easier to remove from streets and pavements, was backed by the Setsquared Partnership, a joint venture capital initiative between Bath, Bristol, Exeter, Southampton and Surrey.
test reg